3 stocks with long-term potential

Before panicking over what a nasty day the market had on Monday, Jim Cramer thinks it is time to take a look at the bright side of the selloff.

The reality is that there has been an epic run recently, and investors were due for a bit of profit taking.

"Please don't pay too much attention to the naysayers who whine about how we don't have enough value in the stock market and how this decline in oil indicates that the global economy is doing much worse than we thought," the "Mad Money" host said.

For instance—Nike, Starbucks and Disney are still winners despite the global environment. They are solid stocks that have all been longtime favorites of Cramer and were all down at some point on Monday. That's despite the fact that they have nothing to do with economic weakness and actually do better amid low oil prices.

Read MoreCramer's bright side to the selloff

Al Monaco, CEO of Enbridge Energy.
Adam Jeffery | CNBC
Al Monaco, CEO of Enbridge Energy.

Given the nasty decline in oil lately, reaching a five-year low on Monday, Jim Cramer feels it is his duty to remind investors not to throw the baby out with the bathwater.

In his opinion, there are still many of the pipeline stocks that are worth owning. Enbridge is one of them. It operates the world's longest crude oil and natural gas liquids pipeline, running through Canada and the U.S. Enbridge was slammed on Monday, down 4 percent on the price of oil.

"But I think this move was a mistake, and the market's mistake is your opportunity," the "Mad Money" host said. To find out more about what could be flowing in the pipeline for Enbridge, Cramer sat down with Enbridge CEO Albert Monaco.

Cramer said Enbridge must not be worried about the price of oil on its business, considering that it just raised its dividend substantially.

"If you look at the dividend increase of 33 percent and then a 14 to 16 percent thereafter; it's really driven by the fact that we have a high degree of certainty," Monaco confirmed.

Read MoreEnbridge CEO to Cramer: We're confident about oil

A researcher works in a microbiology laboratory at the Cubist Pharmaceuticals research facility in Lexington, Massachusetts.
John Guillemin | Bloomberg | Getty Images
A researcher works in a microbiology laboratory at the Cubist Pharmaceuticals research facility in Lexington, Massachusetts.

If there is one person who couldn't be more excited by Merck's acquisition of Cubist Pharma, it's Jim Cramer.

What makes his excitement unique is not only his savvy business sense indicating this was a good deal but also a personal experience that he recently had with his late father.

"I think this morning's purchase of Cubist Pharma for $8.4 billion may be one of the great deals for this old line company," the "Mad Money" host said.

If it weren't for a recent memory of being in the hospital with his father, Cramer would have no idea why Merck would pay so much for Cubist. Especially since its main drug, Cubicin is going off patent in 2018.

Read More Cramer's personal connection to Merck's acquisition

In an effort to have a more well-rounded picture of the impact on falling oil prices on energy companies, Cramer spoke with the CEO of Carrizo Oil and Gas, Chip Johnson.

Carrizo is a player in the Eagle Ford, Niobrara and Utica shales, and is down more than 45 percent in the last six months alone. And while it has had excellent production growth, it does have $1 billion dollars in debt on the balance sheet.

That's huge, considering that it is a $1.53 billion company, and that oil could make up two-thirds of the company's production next year.

The last time the company reported, about a month ago, executives confirmed that they could still generate solid returns with oil at $70 a barrel. Well, now oil has fallen to $63. Can they continue to keep drilling?

"First of all, our stock has fallen a lot less than most of our peers'. We have also worked pretty hard the last three years to get our debt levels down…we also did a lot of hedging this summer in anticipation of the problem, and we are hedged at about 50 percent of our crude production next year, at $92 a barrel," Johnson said.

73783124
Tetra Images | Getty Images

Right now the American Society of Hematology is hosting one of the years most important meetings for the biopharma space in San Francisco. One of the biopharma companies that has become a significant player in blood cancer treatment is Karyopharm Therapeutics.

At the meeting on Monday, it presented strong data supporting its fast rise in share price since it went public 13 months ago at $16 a share; it now trades at $45. The key to its rise was Selinexor, Karyopharm's treatment for various types of blood cancer.

To find out the impact of Selinexor's success, Cramer spoke with Karyopharm CEO Dr. Michael Kauffman.

"The fundamental mechanism of our drug is to work through a series of specialized proteins whose job is normally to detect cells that have DNA damage, and if they do, then they cause those cells to commit suicide… our drug does seem to compliment both the chemotherapy and some of the new targeted therapies as well," Kauffman said.

In the Lightning Round, Cramer gave his take on how oil could impact a few caller favorite stocks:

Consolidated Edison: "It is actually tied to the growth of the area, believe it or not. The fact is that the New York area is doing quite well, and the fact that there are still a lot of places that are switching to oil from natural gas. They do not have any actual dirty power plants out there making the stuff. It is a good stock, though at these prices I cannot like it as much as I did in the $50s. So I am not going to recommend the stock right now."

Xilinx: "Xilinx did deliver on the quarter, when I have been tough on someone ... and then they deliver on the quarter, I have to respect that. The semiconductors are moving, and it's not doing as well as the other semis, but I do think that it's on the right path."

Read MoreLightning Round: Connections to oil?